Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry.

ABSTRACT:

Purpose

Bevacizumab, ranibizumab, and aflibercept are commonly used to treat neovascular age-related macular degeneration (nAMD). The results of various interventional, mostly randomized head-to-head studies, indicate statistical non-inferiority of these three drugs. The results of these studies are often interpreted as the three drugs being freely interchangeable, resulting in some health systems to pressure ophthalmologists to preferentially use the less expensive bevacizumab. This study analyzes switching from aflibercept or ranibizumab to bevacizumab and back under real-world conditions in order to investigate the assumption of interchangeability of the drugs.

Methods

Treatment data of IVT patients with diagnosed nAMD were extracted from the clinical Berlin Macular Regis

SUBMITTER: Riemer T 

PROVIDER: S-EPMC10198863 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature